Skip to main content
. 2021 Jun 21;14(6):2132–2138. doi: 10.1111/cts.13079

FIGURE 1.

FIGURE 1

Plasma concentration‐time profile of daridorexant in control subjects (group A) and in patients with severe renal function impairment (SRFI) on linear scale (on semi‐logarithmic scale in inset). The concentration data were obtained after administration of a single oral dose of 25 mg and are presented as mean ± SD